EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice

Helen Goodluck, Alice Zemljic-Harpf, Ony Araujo Galdino iD, Sadhana Kanoo, Natalia Lopez, Young Chul Kim, Volker Vallon iD

Physiological Reports · 2025-04 · 13 (7)

DOI: 10.14814/phy2.70217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Physiological Reports, online erschienen am 28.03.2025. Verfasst von Helen Goodluck und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology & Hypertension, Department of Medicine, University of California San Diego, and VA San Diego Healthcare System, San Diego, Cal…. Hauptthemen laut MEDLINE: Hypertension, Kidney, Sodium-Glucose Transporter 2 Inhibitors, Glycosides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Lexicon Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual inhibition of sodium glucose cotransporters 1 and 2 (SGLT1/SGLT2) by sotagliflozin protects the kidney and heart in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). To gain mechanistic insights, the current study aimed to establish a murine model of hypertensive CKD that shows cardio‐renal protection by sotagliflozin. Since protection by SGLT2 inhibitors can be diabetes‐independent, a nondiabetic murine model of subtotal nephrectomy with angiotensin II infusion‐facilitated hypertension was followed for 7 weeks. The model showed 40% lower GFR, doubling in plasma FGF23, 50 mmHg higher systolic blood pressure (SBP), 100‐fold increased albuminuria, and robust signs of kidney injury, inflammation, and fibrosis versus sham controls, associated with a 30% larger left cardiac ventricle and wall thickness and upregulation of markers of cardiac overload and fibrosis. Sotagliflozin, initiated 1 week after the last surgery, showed target‐engagement evidenced by glucosuria, 9 mmHg lower SBP, temporal reduction in body weight and GFR, and 30% higher plasma GLP1. Sotagliflozin, however, did not improve markers of kidney injury, inflammation, fibrosis, albuminuria, and plasma FGF23, or signs of cardiac overload, fibrosis, or impaired function. Limited sotagliflozin responsiveness may relate to short treatment time, limited metabolic benefits in nondiabetic setting and/or the model's dominant angiotensin II‐driven effects/hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionKidneySodium-Glucose Transporter 2 InhibitorsGlycosidesRenal Insufficiency, ChronicAnimalsMaleNephrectomyMiceFibroblast Growth Factor-23Disease Models, AnimalMice, Inbred C57BLBlood PressureGlomerular Filtration Rate

Stichwörter der Autor:innen

GFRSGLT1 inhibitionSGLT2 inhibitioncardiac hypertrophykidney injury

Substanzen

Sodium-Glucose Transporter 2 InhibitorsFibroblast Growth Factor-23Fgf23 protein, mouse(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triolGlycosides

Autor:innen und Institutionen

  • Division of Nephrology & Hypertension, Department of Medicine, University of California San Diego, and VA San Diego Healthcare System, San Diego, California, USA.
  • Department of Clinical and Toxicological Analyses, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil.

ORCID-Profile: Ony Araujo Galdino, Volker Vallon

Förderung

  • NIDDK NIH HHS
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Lexicon Pharmaceuticals
  • U.S. Department of Veterans Affairs (VA)
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Goodluck, H., Zemljic-Harpf, A., Galdino, O. A., Kanoo, S., Lopez, N., Kim, Y. C., & Vallon, V. (2025). Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice. Physiological Reports, 13(7). https://doi.org/10.14814/phy2.70217

Vancouver

Goodluck H, Zemljic-Harpf A, Galdino OA, Kanoo S, Lopez N, Kim YC, et al. Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice. Physiological Reports. 2025;13(7). doi:10.14814/phy2.70217

BibTeX
@article{Goodluck2025,
  author = {Goodluck, Helen and Zemljic-Harpf, Alice and Galdino, Ony Araujo and Kanoo, Sadhana and Lopez, Natalia and Kim, Young Chul and Vallon, Volker},
  title = {Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice},
  journal = {Physiological Reports},
  year = {2025},
  volume = {13},
  number = {7},
  doi = {10.14814/phy2.70217}
}
Kostenlos starten →